For employers & health plans

Weight management that scales without the cost spiral

A clinically proven program with published 2-year durability data, plus FDA-approved GLP-1 medication from an independent licensed clinician when a member needs it. $299 per participant per month, all in.

You already know the problem. Obesity-related costs are rising, GLP-1 pharmacy spend is surging, and the programs that work require expensive infrastructure — coaches, clinicians, or indefinite prescriptions. Meanwhile, the programs that scale haven't proven they produce durable outcomes.

Key to Health is different. It's a fully automated digital weight management program built on breath acetone biofeedback — a real-time metabolic signal that teaches people how their food choices affect their body. No coaching. No pharmacotherapy. Published outcomes at 2 years. And marginal cost per additional member that approaches zero.

GLP-1 spending is reshaping employer budgets

GLP-1 medications have demonstrated that significant weight loss is biologically achievable. But real-world employer experience tells a more complicated story: pharmacy budgets are being consumed, adherence is poor, and discontinuation leads to weight regain — negating both clinical and economic benefits.

5–14%
estimated premium increase from GLP-1 coverage alone
~65%
of patients discontinue before 12 weeks — the minimum for meaningful weight loss
1 in 12
members remain on GLP-1 therapy after three years
30%
of employers considering removing GLP-1 weight loss coverage if prices don't change
>50%
of weight lost is regained within a year of stopping GLP-1 therapy
56%
of one school district's total drug spend from just 2% of prescriptions — all GLP-1s

Sources: EBRI/BCBSA simulation model (2025); Blue Health Intelligence claims analysis; Prime Therapeutics persistence data; WTW employer pulse survey (2025); SURMOUNT-4 trial; BCBSA Minnesota school district case.

And the non-pharmacological alternatives have their own gaps

Coaching-based programs

  • Effective when well-implemented, but cost scales linearly with enrollment — every new member requires a human
  • Coach quality varies; high turnover creates inconsistency
  • Difficult to offer to entire eligible population at reasonable per-member cost

App-only programs

  • Scalable and low cost, but limited clinical evidence for durable outcomes
  • Most rely on calorie counting or food logging — high-burden activities with steep dropout
  • No objective metabolic feedback; users are guessing whether their choices are working

A fully automated program with published outcomes

Clinically proven

Key to Health combines a handheld breath acetone sensor with a mobile app that delivers a Mediterranean-style dietary framework — aligned with the 2026 U.S. Dietary Guidelines. When a member breathes into the device, they see a real-time measure of whether their body is burning stored fat. This biofeedback loop creates the behavioral reinforcement that sustains long-term change.

Dietary framework
Mediterranean-style, reduced refined carbs, minimize ultra-processed foods
Real-time biofeedback
Breath sensor measures metabolic response to food choices within hours
Behavior change
Feedback reinforces healthy patterns — published mechanism evidence

The program is entirely self-directed. There is no coaching staff, no physician oversight, and no pharmacotherapy. This means marginal cost per additional member approaches zero — making it feasible to offer to your entire eligible population, not just a high-risk subset.

Clinical data from trial to real-world scale

Published

Randomized controlled trial

Falkenhain et al. Obesity. 2021. Independent investigators at UBC. Funded by CIHR.

A pragmatic RCT comparing Key to Health against WW (an evidence-based active comparator, not placebo). Independently conducted, publicly funded, pre-registered.

155
participants randomized
~10%
total body weight loss at 48 weeks
2.2×
greater weight loss vs. comparator at 12 weeks
Read the published study
Published

Real-world evidence at scale

Wu et al. Obesity. 2026. Co-authored with UBC investigators. Sponsored by Key to Health.

A pre-registered, retrospective cohort study testing whether the RCT findings hold in real-world conditions — at 73× the enrollment, with 2-year follow-up, and with no coaching or physician oversight. Intention-to-treat analysis with MMRM, not just completers.

11,365
adults with BMI ≥25
9.6%
total body weight loss at 2 years
77%
of 2-year completers lost ≥5%
45%
of 2-year completers lost ≥10%

Weight loss reached 9.3% at 1 year and held at 9.6% at 2 years, in line with the RCT. To our knowledge, this is the largest published dataset with standardized 2-year weight outcomes for any non-pharmacological digital weight management program.

Read the published study
Published

Mechanism evidence: why it works

Falkenhain et al. JMIR mHealth and uHealth. 2022.

Mediation analysis showing that biofeedback engagement drove dietary adherence, which drove weight loss. This isn't a black box — there's published evidence for why the program produces outcomes, giving confidence that results are reproducible across populations.

Read the published study

How Key to Health compares

A fair comparison of what we offer versus the alternatives employers and health plans are evaluating.

Key to HealthGLP-1 medicationsCoaching programsApp-only programs
Published RCTYes — active comparatorYes — extensiveVaries by vendorRare
2-year real-world dataYes — 9.6% at 2 years, N=11,365 (published)Limited durability data off-drugRarely publishedRarely published
Fully automatedYes — no humans requiredRequires prescriberNo — coach-dependentYes
Ongoing medicationNoneYes — indefinitely at current evidenceNoneNone
Marginal cost per memberLow$7,000–$12,000+/yearScales with enrollmentLow
Metabolic feedbackReal-time breath acetoneN/AN/AN/A (some use CGM)
Mechanism evidencePublished — mediation analysisWell-characterizedVariesRare
Dietary guideline alignment2026 U.S. Dietary GuidelinesN/A (pharmacological)VariesVaries

This comparison is based on publicly available evidence and general category characteristics. Individual products within each category may differ. GLP-1 cost estimates reflect published commercial pricing analyses.

How it fits into your benefit design

Leading offer

The drug when it's needed. The program for life.

One price covers Key to Health's program, an independent licensed clinician, and FDA-approved GLP-1 medication from Novo Nordisk or Eli Lilly, never compounded. Members start with two months on the program. Those who need medication then qualify for it, and step down off it at goal while the program continues.

$299
per participant per month, all in. No employee copays; billed only for active participants
A third less
than covering Zepbound alone through Lilly's direct-to-employer program ($449/month, before fees)
2 months
on the program first; medication only for members who need it

The program alone produced ~10% weight loss at 48 weeks in an independent RCT and 9.6% at 2 years in 11,365 real-world members. Those results are without medication, not GLP-1 or step-down outcomes.

During & after GLP-1s: behavior skills for maintenance

GLP-1 medications change appetite, but they don't teach dietary skills. When members discontinue — and published data show most do within the first year — they haven't learned what to eat or how their choices affect their metabolism. Key to Health provides the dietary education and real-time metabolic feedback that supports members during GLP-1 therapy and helps them build the habits needed to maintain progress if they step down or discontinue.

Instead of GLP-1s: a standalone evidence-based option

For organizations that have excluded GLP-1 coverage for weight management — or are considering it due to cost — Key to Health offers a clinically studied alternative that can be offered to your entire eligible population. Fully automated, no coaching infrastructure, no ongoing pharmacy spend. Published real-world outcomes show 9.6% average weight loss at 2 years in an intention-to-treat analysis of 11,365 adults.

Interactive

Model your savings

Adjust the inputs below to compare covering GLP-1s alone with Key to Health at $299 per participant per month, all in.

Your population
Total employees 3,000
% seeking or eligible for GLP-1 15%
Annual GLP-1 drug cost per member $6,830
Default $6,830 is the 2025 average net price after rebates (JAMA Health Forum, 2026). Lilly's direct-to-employer price for Zepbound is $5,388 a year ($449/month) before fees.
Without Key to Health
GLP-1 eligible members
450
Annual GLP-1 cost per member
$6,830
Total annual spend
$3.07M
With Key to Health, all in
Total annual spend
—
Why it's lower
Projected annual savings
—
—
Per member per month
—
—

Model compares the same members for 12 months. Key to Health is $299 per participant per month, all in: the program, an independent licensed clinician, and FDA-approved GLP-1 medication when a member qualifies after two months on the program. No employee copays; billed only for active participants (2-month minimum). Program results (~10% weight loss at 48 weeks in an RCT, 9.6% at 2 years in real-world members) are without medication, not GLP-1 or step-down outcomes. Actual costs may vary.

Let's talk about your population

We're happy to walk through our clinical data, model assumptions, and discuss program design with benefits teams, health plan medical directors, and clinical partners.

Get in touch